190 related articles for article (PubMed ID: 35393269)
21. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
[TBL] [Abstract][Full Text] [Related]
22. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
[TBL] [Abstract][Full Text] [Related]
23. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
Armstrong A; Paul C; Puig L; Boehncke WH; Freeman M; Torii H; Papp K; Griffiths CEM; Blauvelt A; Reich K; Gooderham M; Terui T; Renda L; Agada N; Xu W; Gallo G; Lebwohl MG
Dermatol Ther (Heidelb); 2020 Feb; 10(1):133-150. PubMed ID: 31749092
[TBL] [Abstract][Full Text] [Related]
24. Ixekizumab in the treatment of psoriatic arthritis.
Lespessailles E; Toumi H
Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
[TBL] [Abstract][Full Text] [Related]
25. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
[TBL] [Abstract][Full Text] [Related]
26. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
[TBL] [Abstract][Full Text] [Related]
27. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Rosmarin D; Lebwohl M; Peterson L; Madden C; de Cuyper D; Davies O; Thaçi D
Br J Dermatol; 2024 Mar; 190(4):477-485. PubMed ID: 37950894
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
[TBL] [Abstract][Full Text] [Related]
29. The safety of ixekizumab in psoriasis drug therapy.
Puig L
Expert Opin Drug Saf; 2020 Feb; 19(2):117-130. PubMed ID: 31874129
[No Abstract] [Full Text] [Related]
30. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
31. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Wu S; Xu Y; Yang L; Guo L; Jiang X
Front Immunol; 2023; 14():1294416. PubMed ID: 38106423
[TBL] [Abstract][Full Text] [Related]
32. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
33. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
[TBL] [Abstract][Full Text] [Related]
34. Ixekizumab for the treatment of psoriasis: up-to-date.
Craig S; Warren RB
Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
[No Abstract] [Full Text] [Related]
35. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Langley RG; Kimball AB; Nak H; Xu W; Pangallo B; Osuntokun OO; Agada N; Reich K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):333-339. PubMed ID: 30198588
[TBL] [Abstract][Full Text] [Related]
36. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
[TBL] [Abstract][Full Text] [Related]
38. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Paul C; Griffiths CEM; van de Kerkhof PCM; Puig L; Dutronc Y; Henneges C; Dossenbach M; Hollister K; Reich K
J Am Acad Dermatol; 2019 Jan; 80(1):70-79.e3. PubMed ID: 29969700
[TBL] [Abstract][Full Text] [Related]
39. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study.
Hansen RL; Jørgensen TS; Egeberg A; Rosenø NAL; Skougaard M; Stisen ZR; Dreyer L; Kristensen LE
Rheumatology (Oxford); 2024 May; 63(6):1593-1598. PubMed ID: 37647648
[TBL] [Abstract][Full Text] [Related]
40. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
